Trial · NCT05349721
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Combined Assessment of Function (ALS Functional Rating Scale-Revised [ALSFRS-R]) and Survival (CAFS) Rank After 24 Weeks of Treatment (Intention-to-Treat [ITT] 1 Analysis Population) | Utreloxastat | 172.22 | Standard Error 13.25 | units on a scale | |
| Combined Assessment of Function (ALS Functional Rating Scale-Revised [ALSFRS-R]) and Survival (CAFS) Rank After 24 Weeks of Treatment (Intention-to-Treat [ITT] 1 Analysis Population) | Placebo | 165.36 | Standard Error 14.65 | units on a scale | |
| Combined Assessment of Function (ALSFRS-R) and Survival (CAFS) Rank After 24 Weeks of Treatment (ITT2 Analysis Population) | Utreloxastat | 188.58 | Standard Error 14.81 | units on a scale | |
| Combined Assessment of Function (ALSFRS-R) and Survival (CAFS) Rank After 24 Weeks of Treatment (ITT2 Analysis Population) | Placebo | 181.89 | Standard Error 15.96 | units on a scale | |
| Change From Baseline in ALSFRS-R Score at Week 24 (ITT1 Analysis Population) | Utreloxastat | 29.4 | Standard Error 0.73 | units on a scale | |
| Change From Baseline in ALSFRS-R Score at Week 24 (ITT1 Analysis Population) | Placebo | 31.4 | Standard Error 0.93 | units on a scale | |
| Change From Baseline in ALSFRS-R Score at Week 24 (ITT2 Analysis Population) | Utreloxastat | 27.7 | Standard Error 0.71 | units on a scale | |
| Change From Baseline in ALSFRS-R Score at Week 24 (ITT2 Analysis Population) | Placebo | 29.1 | Standard Error 0.88 | units on a scale | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Utreloxastat | 174 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | 90 | Participants | ||
| Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 24 | Utreloxastat | -14.62 | Standard Error 2.106 | percent predicted SVC | |
| Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 24 | Placebo | -15.92 | Standard Error 2.518 | percent predicted SVC | |
| Change From Baseline in Modified Norris Scale Total Score at Week 24 | Utreloxastat | -18.2 | Standard Error 1.57 | units on a scale | |
| Change From Baseline in Modified Norris Scale Total Score at Week 24 | Placebo | -18.0 | Standard Error 1.82 | units on a scale | |
| Overall Survival Rate | Utreloxastat | 95.8 | 95% Confidence Interval 92.9 to 98.6 | percentage of participants | |
| Overall Survival Rate | Placebo | 97.9 | 95% Confidence Interval 95.1 to 100.0 | percentage of participants | |
| Overall Survival | Utreloxastat | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival | Placebo | NA | 95% Confidence Interval NA to NA | months | |
| Change From Baseline in ALS Assessment Questionnaire (ALSAQ-40) Total Score at Week 24 | Utreloxastat | 27.9 | Standard Error 3.05 | units on a scale | |
| Change From Baseline in ALS Assessment Questionnaire (ALSAQ-40) Total Score at Week 24 | Placebo | 23.9 | Standard Error 3.48 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05349721/results